Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in Thrombocytopenic Subjects With HCV
NCT00996216Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2009
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of eltrombopag in Thrombocytopenia, sponsored by GSK. Primary endpoints: Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part 1 up to 9 weeks, Number of Participants With Any AE and Any SAE in Part 2 and 6 more. Started Sep 2009; status: completed.
02
Drugs
eltrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT00996216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00996216.